Cargando…

Current Advances in Aptamers for Cancer Diagnosis and Therapy

Nucleic acid aptamers are single-stranded oligonucleotides that interact with target molecules with high affinity and specificity in unique three-dimensional structures. Aptamers are generally isolated by a simple selection process called systematic evolution of ligands by exponential enrichment (SE...

Descripción completa

Detalles Bibliográficos
Autores principales: Hori, Shin-ichiro, Herrera, Alberto, Rossi, John J., Zhou, Jiehua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789359/
https://www.ncbi.nlm.nih.gov/pubmed/29301363
http://dx.doi.org/10.3390/cancers10010009
_version_ 1783296259376807936
author Hori, Shin-ichiro
Herrera, Alberto
Rossi, John J.
Zhou, Jiehua
author_facet Hori, Shin-ichiro
Herrera, Alberto
Rossi, John J.
Zhou, Jiehua
author_sort Hori, Shin-ichiro
collection PubMed
description Nucleic acid aptamers are single-stranded oligonucleotides that interact with target molecules with high affinity and specificity in unique three-dimensional structures. Aptamers are generally isolated by a simple selection process called systematic evolution of ligands by exponential enrichment (SELEX) and then can be chemically synthesized and modified. Because of their high affinity and specificity, aptamers are promising agents for biomarker discovery, as well as cancer diagnosis and therapy. In this review, we present recent progress and challenges in aptamer and SELEX technology and highlight some representative applications of aptamers in cancer therapy.
format Online
Article
Text
id pubmed-5789359
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-57893592018-02-02 Current Advances in Aptamers for Cancer Diagnosis and Therapy Hori, Shin-ichiro Herrera, Alberto Rossi, John J. Zhou, Jiehua Cancers (Basel) Review Nucleic acid aptamers are single-stranded oligonucleotides that interact with target molecules with high affinity and specificity in unique three-dimensional structures. Aptamers are generally isolated by a simple selection process called systematic evolution of ligands by exponential enrichment (SELEX) and then can be chemically synthesized and modified. Because of their high affinity and specificity, aptamers are promising agents for biomarker discovery, as well as cancer diagnosis and therapy. In this review, we present recent progress and challenges in aptamer and SELEX technology and highlight some representative applications of aptamers in cancer therapy. MDPI 2018-01-03 /pmc/articles/PMC5789359/ /pubmed/29301363 http://dx.doi.org/10.3390/cancers10010009 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Hori, Shin-ichiro
Herrera, Alberto
Rossi, John J.
Zhou, Jiehua
Current Advances in Aptamers for Cancer Diagnosis and Therapy
title Current Advances in Aptamers for Cancer Diagnosis and Therapy
title_full Current Advances in Aptamers for Cancer Diagnosis and Therapy
title_fullStr Current Advances in Aptamers for Cancer Diagnosis and Therapy
title_full_unstemmed Current Advances in Aptamers for Cancer Diagnosis and Therapy
title_short Current Advances in Aptamers for Cancer Diagnosis and Therapy
title_sort current advances in aptamers for cancer diagnosis and therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789359/
https://www.ncbi.nlm.nih.gov/pubmed/29301363
http://dx.doi.org/10.3390/cancers10010009
work_keys_str_mv AT horishinichiro currentadvancesinaptamersforcancerdiagnosisandtherapy
AT herreraalberto currentadvancesinaptamersforcancerdiagnosisandtherapy
AT rossijohnj currentadvancesinaptamersforcancerdiagnosisandtherapy
AT zhoujiehua currentadvancesinaptamersforcancerdiagnosisandtherapy